CCLD vs DBVT vs ALKS vs HCAT

For growth investors, CareCloud, Inc.

(CCLD) is the stronger pick with 8. 7% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). CareCloud, Inc. (CCLD) offers the better valuation at 23. 6x trailing P/E (13. 5x forward), making it the more compelling value choice. Analysts rate CareCloud, Inc. (CCLD) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, CareCloud, Inc.

(CCLD) is the cheapest at 23. 6x versus Alkermes plc at 24. 5x. On forward P/E, CareCloud, Inc. is actually cheaper at 13. 5x.

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +61.

7%, compared to -97. 0% for Health Catalyst, Inc. (HCAT). Over 10 years, the gap is even starker: CCLD returned +142. 5% versus HCAT's -96. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

00β versus Health Catalyst, Inc. 's 1. 93β — meaning HCAT is approximately 93% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CareCloud, Inc.

(CCLD) is pulling ahead at 8. 7% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: CareCloud, Inc. grew EPS 135. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -57. 2% for Health Catalyst, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -51. 7% for HCAT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, CareCloud, Inc.

(CCLD) trades at 13. 5x forward P/E versus 13. 5x for Health Catalyst, Inc. — 0. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 134. 8% to $46. 33.

In this comparison, CCLD (0.

7% yield) pays a dividend. DBVT, ALKS, HCAT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CareCloud, Inc.

(CCLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 28), 0. 7% yield, +142. 5% 10Y return). Health Catalyst, Inc. (HCAT) carries a higher beta of 1. 93 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CCLD: +142. 5%, HCAT: -96. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

CCLD pays a dividend while DBVT, ALKS, HCAT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.